These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 19046739)

  • 21. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials.
    Padwal R; Li SK; Lau DC
    Int J Obes Relat Metab Disord; 2003 Dec; 27(12):1437-46. PubMed ID: 12975638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obesity: a review of pathogenesis and management strategies.
    Kaila B; Raman M
    Can J Gastroenterol; 2008 Jan; 22(1):61-8. PubMed ID: 18209783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Managing type 2 diabetes mellitus in patients with obesity.
    Hauner H
    Treat Endocrinol; 2004; 3(4):223-32. PubMed ID: 16026105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Orlistat and sibutramine beyond weight loss.
    Mannucci E; Dicembrini I; Rotella F; Rotella CM
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treating obesity in the family practice setting.
    Fernstrom MH
    Postgrad Med; 2001 Jun; 109(6 Suppl):10-8. PubMed ID: 19667563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action.
    Grams J; Garvey WT
    Curr Obes Rep; 2015 Jun; 4(2):287-302. PubMed ID: 26627223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacotherapy of obesity.
    Finer N
    Best Pract Res Clin Endocrinol Metab; 2002 Dec; 16(4):717-42. PubMed ID: 12468417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combining behavioral and pharmacological treatments for obesity.
    Phelan S; Wadden TA
    Obes Res; 2002 Jun; 10(6):560-74. PubMed ID: 12055334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What are the risks and the benefits of current and emerging weight-loss medications?
    Robinson JR; Niswender KD
    Curr Diab Rep; 2009 Oct; 9(5):368-75. PubMed ID: 19793507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological intervention: the antiobesity approach.
    Rissanen A
    Eur J Clin Invest; 1998 Sep; 28 Suppl 2():27-30. PubMed ID: 9777325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
    Wadden TA; Berkowitz RI; Womble LG; Sarwer DB; Arnold ME; Steinberg CM
    Obes Res; 2000 Sep; 8(6):431-7. PubMed ID: 11011909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacotherapy for obesity in menopausal women.
    Samat A; Rahim A; Barnett A
    Menopause Int; 2008 Jun; 14(2):57-62. PubMed ID: 18519266
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weight loss maintenance.
    Grief SN; Miranda RL
    Am Fam Physician; 2010 Sep; 82(6):630-4. PubMed ID: 20842990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women.
    Sari R; Balci MK; Cakir M; Altunbas H; Karayalcin U
    Endocr Res; 2004 May; 30(2):159-67. PubMed ID: 15473126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacotherapy in the treatment of obesity].
    Hamann A
    MMW Fortschr Med; 2006 Mar; 148(9):36-8. PubMed ID: 16566392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent advances in obesity pharmacotherapy.
    Mayer MA; Höcht C; Puyó A; Taira CA
    Curr Clin Pharmacol; 2009 Jan; 4(1):53-61. PubMed ID: 19149502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.
    Erondu N; Addy C; Lu K; Mallick M; Musser B; Gantz I; Proietto J; Astrup A; Toubro S; Rissannen AM; Tonstad S; Haynes WG; Gottesdiener KM; Kaufman KD; Amatruda JM; Heymsfield SB
    Obesity (Silver Spring); 2007 Aug; 15(8):2027-42. PubMed ID: 17712121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obesity and pharmacologic therapy.
    Thearle M; Aronne LJ
    Endocrinol Metab Clin North Am; 2003 Dec; 32(4):1005-24. PubMed ID: 14711072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes.
    Nelson RH; Miles JM
    Expert Opin Pharmacother; 2005 Nov; 6(14):2483-91. PubMed ID: 16259579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.